Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
Teladoc Health (NYSE:TDOC) announced an employment inducement award effective November 1, 2025 for new Chief Technology Officer Dave Ross. The grant includes 86,906 restricted stock units (RSUs) and 86,906 performance stock units (PSUs) at target (up to 173,812 shares if maximum is earned).
The RSUs vest with one-third on the first anniversary and the remainder quarterly over the next two years. The PSUs are earned over a three-year performance period based on specified financial metrics. The award was approved by the Compensation Committee and granted under the Teladoc Health 2023 Employment Inducement Incentive Award Plan as permitted by NYSE Rule 303A.08.
Teladoc Health (NYSE:TDOC) ha annunciato un award di inducement all'occupazione efficace 1 novembre 2025 per il nuovo Chief Technology Officer Dave Ross. L'assegnazione include 86,906 restricted stock units (RSUs) e 86,906 performance stock units (PSUs) a target (fino a 173,812 azioni se viene raggiunto il massimo). Le RSU vestono con un terzo al primo anniversario e il resto trimestralmente nei successivi due anni. Le PSU si maturano durante un periodo di performance di tre anni basato su metriche finanziarie specificate. L'assegnazione è stata approvata dal Compensation Committee e concessa ai sensi del Teladoc Health 2023 Employment Inducement Incentive Award Plan come consentito da NYSE Rule 303A.08.
Teladoc Health (NYSE:TDOC) anunció una concesión de incentivos de empleo efectiva el 1 de noviembre de 2025 para el nuevo Chief Technology Officer Dave Ross. La adjudicación incluye 86,906 restricted stock units (RSUs) y 86,906 unidades de acciones de rendimiento (PSUs) a objetivo (hasta 173,812 acciones si se obtiene el máximo). Las RSU vencen con un tercio en el primer aniversario y el resto trimestralmente durante los dos años siguientes. Las PSU se obtienen durante un período de rendimiento de tres años basado en métricas financieras especificadas. La concesión fue aprobada por el Compensation Committee y otorgada en virtud del Teladoc Health 2023 Employment Inducement Incentive Award Plan, como permitido por NYSE Rule 303A.08.
Teladoc Health (NYSE:TDOC)가 새로운 최고기술책임자 Dave Ross를 위한 고용 유인 보상을 2025년 11월 1일에 발효했다고 발표했습니다. 수여에는 86,906개의 RSU와 목표 달성 시 86,906개의 PSU가 포함되며(최대 달성 시 173,812주까지). RSU는 첫 해 기념일에 3분의 1이 vest되고 남은 부분은 향후 2년 동안 분기별로 vest됩니다. PSU는 특정 재무 지표를 바탕으로 3년 성과 기간 동안 획득됩니다. 이 수상은 보상위원회가 승인했으며 NYSE 규칙 303A.08에 따라 Teladoc Health 2023 Employment Inducement Incentive Award Plan에 따라 수여되었습니다.
Teladoc Health (NYSE:TDOC) a annoncé une attribution d’incitation à l’emploi effective le 1er novembre 2025 pour le nouveau directeur technologique, Dave Ross. L’octroi comprend 86 906 unités d’actions restreintes (RSU) et 86 906 unités d’actions de performance (PSU) à l’objectif (jusqu’à 173 812 actions si le maximum est atteint). Les RSU se vestent avec un tiers à la première anniversaire et le reste trimestriellement sur les deux années suivantes. Les PSU sont acquises sur une période de performance de trois ans basée sur des métriques financières spécifiées. L’attribution a été approuvée par le comité de rémunération et accordée en vertu du Teladoc Health 2023 Employment Inducement Incentive Award Plan tel que permis par la NYSE Rule 303A.08.
Teladoc Health (NYSE:TDOC) kündigte eine Beschäftigungsanreiz-Zuwendung an, die ab dem 1. November 2025 wirksam wird, für den neuen Chief Technology Officer Dave Ross. Die Zuwendung umfasst 86.906 RSUs und 86.906 PSUs auf Ziel (bis zu 173.812 Aktien, wenn das Maximum erreicht wird). Die RSUs vesten in einem Drittel zum ersten Jahrestag und der Rest wird in den folgenden zwei Jahren vierteljährlich vestet. Die PSUs werden über eine dreijährige Leistungsperiode basierend auf festgelegten Finanzkennzahlen verdient. Die Zuwendung wurde vom Vergütungsausschuss genehmigt und gemäß dem Teladoc Health 2023 Employment Inducement Incentive Award Plan gewährt, wie durch NYSE Rule 303A.08 gestattet.
أعلنت Teladoc Health (بورصة نيويورك: TDOC) عن منحة حافز توظيف سارية اعتبارًا من 1 نوفمبر 2025 للمدير التنفيذي الجديد للتكنولوجيا Dave Ross. تتضمن المنحة 86,906 وحدة أسهم مقيدة (RSUs) و 86,906 وحدة أسهم أداء (PSUs) عند الهدف (حتى 173,812 سهماً إذا تم تحقيق الحد الأقصى). تتفكك RSUs بتثبيت ثلثها في الذكرى الأولى والباقي ربعياً على مدى العامين التالية. تُكتسب PSUs خلال فترة أداء لمدة ثلاث سنوات بناءً على مقاييس مالية محددة. تمت الموافقة على الجوائز من قبل لجنة التعويض ومنحت وفقًا لـ Teladoc Health 2023 Employment Inducement Incentive Award Plan كما تسمح به NYSE Rule 303A.08.
- None.
- None.
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.
Effective November 1, 2025, in connection with commencing employment as Chief Technology Officer, Dave Ross was granted an award of restricted stock units covering 86,906 shares of Teladoc Health’s common stock, par value
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Media:
Lou Serio
202-569-9715
pr@teladochealth.com
FAQ
What did Teladoc Health (TDOC) grant Dave Ross as an inducement award on November 1, 2025?
What is the RSU vesting schedule for the TDOC inducement award to Dave Ross?
Over what period are the TDOC performance stock units for Dave Ross measured?
Under which plan and NYSE rule was the TDOC inducement award granted?
How many total shares could be issued if Dave Ross's TDOC PSUs pay out at maximum?
Who approved the inducement award for the new TDOC CTO and when did it take effect?
